Vect-Horus: Innovative Biotechnology Company Showcasing at Viva Technology Conference in Paris
Vect-Horus, a biotechnology company based in Marseille, France, has announced its participation at the Viva Technology conference in Paris from May 22-25, 2024.
France’s National Center for Scientific Research (CNRS) has selected 10 startups with innovative technologies to showcase at the event. Among them is Vect-Horus, which will present its VECTrans® technology at the conference.
Vect-Horus was founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University). The company focuses on developing vectors for targeting and delivering therapeutic or imaging agents to organs and tumors. With 38 employees predominantly in research and development, Vect-Horus continues to make strides in the biotechnology field.
Jean-Manuel Pean, Chief Scientific Officer of Vect-Horus, will be part of a roundtable discussion at the conference where he will provide an overview of the company’s pipeline. He will discuss progress made with the VECTrans® technology, early clinical trials of their theragnostic agent for glioblastoma and pancreatic cancer, and provide updates on their partnerships including agreements with Novo Nordisk and Ionis Pharmaceuticals. The detailed roundtable program will be announced closer to the event.
For more information about Vect-Horus or media inquiries or press releases contact [vect@vecthorus.com](mailto:vect@vecthorus.com) or reach out to their Business Development and Alliance Manager Emmanuelle Bettendorf or Cohesion Bureau’s media relations team for any other information.
